Search companies

Live

Tuesday, 17 November 2026 · 582 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Orthocell Partner Wins U.S. Clearance, Opening PearlBone’s Path to Market

OCC: $0.570 +0.00% · MC: $155M

Marine Biomedical has received U.S. FDA clearance to market its PearlBone bone graft substitute for cleared indications, advancing it towards commercialisation. Orthocell holds a 12% stake and first right of refusal over global distribution rights, but any role in a launch depends on exercising those rights and agreeing commercial terms. The clearance adds a potential bone-repair product to Orthocell’s nerve and tendon portfolio; its U.S. Remplir sales also recently reached a record month, up 84% on the Q1 FY27 monthly average.

Source announcements: 2026-11-03 10:09 to 2026-11-03 10:09 Sydney time
Story updated 2026-11-03 10:11 Sydney time
SourcesMarine Biomedical Achieves FDA Clearance
Comments